Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation 15
Figure 4. North America Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 17
Figure 5. North America Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 20
Figure 6. Impact of COVID-19 on Business 24
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical Manufacturing Industry 26
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical Manufacturing Industry 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical Manufacturing Industry 36
Figure 11. Breakdown of North America Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue 41
Figure 12. Contribution to North America 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%) 41
Figure 13. North America Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn 42
Figure 14. North America Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn 43
Figure 15. North America Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn 44
Figure 16. North America Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn 45
Figure 17. North America Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn 46
Figure 18. North America Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn 47
Figure 19. North America Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn 48
Figure 20. Breakdown of North America Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue 50
Figure 21. Contribution to North America 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%) 50
Figure 22. North America Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn 51
Figure 23. North America Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn 52
Figure 24. North America Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn 53
Figure 25. North America Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn 54
Figure 26. North America Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn 55
Figure 27. Breakdown of North America Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue 56
Figure 28. Contribution to North America 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%) 57
Figure 29. North America Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn 58
Figure 30. North America Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn 59
Figure 31. North America Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn 60
Figure 32. Breakdown of North America Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue 62
Figure 33. Contribution to North America 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 62
Figure 34. North America Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn 63
Figure 35. North America Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn 64
Figure 36. North America Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn 65
Figure 37. North America Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn 66
Figure 38. North America Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn 67
Figure 39. North America Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn 68
Figure 40. North America Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn 69
Figure 41. North America Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn 70
Figure 42. Breakdown of North America Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue 71
Figure 43. Contribution to North America 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 72
Figure 44. North America Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn 73
Figure 45. North America Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn 74
Figure 46. North America Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn 75
Figure 47. Breakdown of North America Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue 76
Figure 48. Contribution to North America 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%) 77
Figure 49. North America Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn 78
Figure 50. North America Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn 79
Figure 51. Breakdown of North America Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue 81
Figure 52. Contribution to North America 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%) 81
Figure 53. North America Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn 82
Figure 54. North America Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn 83
Figure 55. Breakdown of North America Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue 85
Figure 56. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 86
Figure 57. U.S. Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 88
Figure 58. Canada Pharmaceutical Manufacturing Industry, 2017-2027, $ bn 91
Figure 59. Pharmaceutical Manufacturing Industry in Mexico, 2017-2027, $ bn 93
Figure 60. Growth Stage of North America Industrial Robot Software Industry over the Forecast Period 95
North America pharmaceutical manufacturing industry is expected to grow by 11.0% annually in the forecast period and reach $241.76 billion by 2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic. Highlighted with 26 tables and 60 figures, this 125-page report “North America Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Industry Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Industry Opportunities • Porter’s Fiver Forces The trend and outlook of North America industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country. Based on Formulation, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Tablets • Capsules • Injectable • Sprays • Suspensions • Powders • Other Formulations Based on Route of Administration, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Oral Medicine • Topical Medicine • Parenteral Medicine • Inhalations • Other Routes of Administration Based on Age Group, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Children & Adolescents • Adults • Geriatric Based on Therapeutic Application, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Cardiovascular Diseases • Pain • Diabetes • Cancer • Respiratory Diseases • Neurological Diseases • Orthopedics • Other Applications Based on Drug Type, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Branded Prescription Drugs • Generic Prescription Drugs • OTC Drugs Based on Distribution Channels, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • Retail Channels • Non-retail Channels Based on Manufacturing Facility, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section. • In-house Facility • Outsourced Facility Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players. Specifically, potential risks associated with investing in North America pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): Abbott Laboratories Aenova Group Amgen AstraZeneca Catalent Inc. Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead Sciences GlaxoSmithKline plc Johnson & Johnson Lonza Group Lupin Merck & Co., Inc. Novartis AG Novo Nordisk Pfizer, Inc. Roche Sanofi SA Takeda (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More